Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atrium given exclusive rights

This article was originally published in The Tan Sheet

Executive Summary

Atrium Innovations will be able to "accelerate its growth and development" in the U.S. following an American court ruling allowing the firm to sell enzyme-based supplement Wobenzym N in the country, the Canadian firm announces Nov. 15. Concurrently, Marlyn Neutraceuticals is ordered to stop using the Wobenzym N trademark and selling products under the brand name. Wobenzym N, a product intended to benefit the health of joints, muscles and tendons, was developed by German company Mucos, which Atrium acquired for $175 million in July 2007. At the time, the firm projected the purchase would accelerate its earnings by approximately $27 million (1"The Tan Sheet," July 23, 2007, In Brief). Annual European sales of Wobenzym N currently are more than $90 million...

You may also be interested in...

Atrium re-evaluates business

In an effort to better position itself as a leader in the health and nutritional products arena, Atrium Innovations is considering a sale of its active ingredients and specialty chemicals division, the Canadian nutritional products marketer announces Dec. 18. A sale of the division would "strengthen Atrium with a targeted vision and development strategy in the high potential nutritional supplements market," the Quebec-based firm says, noting it plans to act as a consolidator in the fragmented segment. Atrium strengthened its health division with the purchase of German-based Mucos in July and was recently granted permission to sell Mucos' enzyme-based supplement Wobenzym N in the U.S. (1"The Tan Sheet" Nov. 26, 2007, In Brief)...

Atrium goes to Germany

Atrium Innovations will expand its operations into Germany with the $175 mil. acquisition of German OTC and dietary supplements maker Mucos Emulsions, Atrium announces July 12. The acquisition gives Atrium a "privileged access to the German market, the largest European market for dietary supplements," and allows the firm to establish its European Health and Nutrition Division, the company says. Mucos' top brand is Wobenzym, "Germany's most popular natural anti-inflammatory product," and Atrium expects the buy to increase its earnings by approximately $27 mil., the firm says. The deal "should be followed by further acquisitions and strong organic growth as we did in the United States and Canada," Atrium CEO Pierre Fitzgibbon says...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts